CG Oncology Stock Forward View - Price Action Indicator
| CGON Stock | 51.50 0.12 0.23% |
CGON Stock outlook is based on your current time horizon.
As of today the rsi of CG Oncology's share price is below 20 suggesting that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Using CG Oncology hype-based prediction, you can estimate the value of CG Oncology Common from the perspective of CG Oncology response to recently generated media hype and the effects of current headlines on its competitors.
CG Oncology after-hype prediction price | USD 51.75 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of CG Oncology to cross-verify your projections. CG Oncology Additional Predictive Modules
Most predictive techniques to examine CGON price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for CGON using various technical indicators. When you analyze CGON charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Previous Price Action Indicator | Price Action Indicator | Trend |
| (0.25) | (0.23) |
| Check CG Oncology Volatility | Backtest CG Oncology | Information Ratio |
CG Oncology Trading Date Momentum
| On February 16 2026 CG Oncology Common was traded for 51.50 at the closing time. The top price for the day was 52.77 and the lowest listed price was 50.58 . There was no trading activity during the period 0.0. Lack of trading volume on February 16, 2026 did not affect price variability. The overall trading delta against the current closing price is 0.31% . |
Price Action Indicator (or PAIN) was developed by Michael B. Geraty and published in 'Futures' magazine in August 1997.
| Compare CG Oncology to competition |
Other Forecasting Options for CG Oncology
For every potential investor in CGON, whether a beginner or expert, CG Oncology's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. CGON Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in CGON. Basic forecasting techniques help filter out the noise by identifying CG Oncology's price trends.CG Oncology Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CG Oncology stock to make a market-neutral strategy. Peer analysis of CG Oncology could also be used in its relative valuation, which is a method of valuing CG Oncology by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
CG Oncology Market Strength Events
Market strength indicators help investors to evaluate how CG Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading CG Oncology shares will generate the highest return on investment. By undertsting and applying CG Oncology stock market strength indicators, traders can identify CG Oncology Common entry and exit signals to maximize returns.
CG Oncology Risk Indicators
The analysis of CG Oncology's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in CG Oncology's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting cgon stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 2.79 | |||
| Semi Deviation | 2.41 | |||
| Standard Deviation | 4.68 | |||
| Variance | 21.86 | |||
| Downside Variance | 7.87 | |||
| Semi Variance | 5.8 | |||
| Expected Short fall | (3.57) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for CG Oncology
The number of cover stories for CG Oncology depends on current market conditions and CG Oncology's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that CG Oncology is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about CG Oncology's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
CG Oncology Short Properties
CG Oncology's future price predictability will typically decrease when CG Oncology's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of CG Oncology Common often depends not only on the future outlook of the potential CG Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. CG Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 62.5 M | |
| Cash And Short Term Investments | 742 M |
Check out Historical Fundamental Analysis of CG Oncology to cross-verify your projections. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Will Biotechnology sector continue expanding? Could CGON diversify its offerings? Factors like these will boost the valuation of CG Oncology. Projected growth potential of CGON fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CG Oncology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate CG Oncology Common using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CG Oncology's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause CG Oncology's market price to deviate significantly from intrinsic value.
It's important to distinguish between CG Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CG Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CG Oncology's market price signifies the transaction level at which participants voluntarily complete trades.